REGENXBIO Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $0.12 | $0.43 | +258.3% | Beat |
| Q12026 FY2026 | $-1.36 | $-1.72 | -26.5% | Miss |
| Q42025 FY2025 | $-1.01 | $-1.30 | -28.7% | Miss |
Back to RGNX overview · RGNX holders · RGNX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.